LVADs Spawn Mergers: WorldHeart/MedQuest And MicroMed/Salmon Express
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart's acquisition of LVAD developer MedQuest will accelerate the firm's development of a second-generation ventricular assist device, according to CEO Jal Jassawalla
You may also be interested in...
FDA Expands Inclusion Criteria For WorldHeart LVAS Destination Therapy Trial
FDA has given conditional approval for WorldHeart to modify its pivotal trial of the Novacor implantable heart-assist pump. The changes are expected to accelerate the study, which has moved slowly since its start in 2004
FDA Expands Inclusion Criteria For WorldHeart LVAS Destination Therapy Trial
FDA has given conditional approval for WorldHeart to modify its pivotal trial of the Novacor implantable heart-assist pump. The changes are expected to accelerate the study, which has moved slowly since its start in 2004
Arrow Contemplates Fate Of LVAD Business; WorldHeart, Thoratec Start Trials
Arrow International's board of directors will assess the future commercial potential of its left-ventricular assist devices at a meeting April 6-7